Merck To Acquire US Biopharma Company SpringWorks Therapeutics To Accelerate Sustainable Growth Of Healthcare Business
Purchase price of $47 per share in cash represents an enterprise value of €3.0B ($3.4B), or an equity value of approximately $3.9B Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for Merck’s Healthcare business …